WAVEMAN · COMPANY

BNKK · Bonk, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

BNKK

Name: BONK, INC. (BNKK) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BONK, INC.

PHARMA & BIOTECH · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · CIK 0001760903

SEC FILINGS☆ WATCH

INSIDER NET · 180D

$148.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+201.6%

XBRL, annual

NET MARGIN

-3220.4%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$148.3K over 180 days

+$60.7K over 90 days · +$148.3K of it by a 10%+ holder

more than 78% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

13 funds added or opened last quarter

below 78% of Pharma & Biotech

REVENUE

+201.6% year over year

more than 90% of Pharma & Biotech

MARGIN

-3220.4% net margin

below 96% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

2.4% of shares outstanding short · 3.3 days to cover · settled 2026-07-31

below 61% of Pharma & Biotech

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -91.1%

-91.1%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $148.3K bought by insiders over 180 days, 13 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BONK, INC. insiders bought a net $148.3K of stock across 9 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Rudy Mitchell Austin

Director

BUY

2026-07-13

9,000.0

$10.9K

Rudy Mitchell Austin

Director

BUY

2026-07-10

1,000.0

$1.2K

Rudy Mitchell Austin

Director

BUY

2026-07-02

11,659.0

$17.1K

Rudy Mitchell Austin

Director

BUY

2026-06-22

2,500.0

$3.9K

Rudy Mitchell Austin

Director

BUY

2026-06-22

2,500.0

$3.9K

9 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 4 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

LPL Financial LLC

117,020.0 sh

$177.9K

UBS Group AG

104,761.0 sh

$159.2K

VANGUARD CAPITAL MANAGEMENT LLC

95,620.0 sh

$145.3K

CITADEL ADVISORS LLC

51,275.0 sh

$77.9K

GEODE CAPITAL MANAGEMENT, LLC

50,658.0 sh

$77.0K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$113.7K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$121.1K POSITION · AS OF 2026-03-31

0.0%

Total Stock Market Index Trust

$407 POSITION · AS OF 2026-03-31

0.0%

Fidelity Series Total Market Index Fund

$26.8K POSITION · AS OF 2026-02-28

0.0%

Fidelity Total Market Index Fund

$23.0K POSITION · AS OF 2026-02-28

0.0%

Fidelity Nasdaq Composite Index Fund

$2.8K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.1M	$702.0K	$202.7K	$120.6K
GROSS PROFIT	$1.2M	$-2.4M	$-74.5K	$-204.5K
NET INCOME	$-68.2M	$-49.4M	$-15.1M	$-15.2M
EPS (DILUTED)	-17.02	-31.77	-0.49	-0.69
OPERATING CASH FLOW	$-25.3M	$-18.1M	$-10.5M	$-6.4M
BUYBACKS	—	—	—	$2.9M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE